Registration, quality assurance and the shape of a medicines contract
A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programs -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.
Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.
The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and program funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.
This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.
Who buys pharmaceuticals in Denmark?
GlobalGov holds 1,166 pharmaceuticals records from 65 distinct buying organizations in Denmark. The most frequent publishers are Amgros I/S (869 records); Amgros I/S (46 records); Socialstyrelsen (19 records); Statens Serum Institut (7 records); Biofos A/S (5 records); Guldborgsund Forsyning A/S (5 records). Between them the 6 largest account for 82% of everything published, so buying here is concentrated in a few authorities.
| Buying organization | Records | Share |
|---|---|---|
| Amgros I/S | 869 | 75% |
| Amgros I/S | 46 | 3.9% |
| Socialstyrelsen | 19 | 1.6% |
| Statens Serum Institut | 7 | 0.6% |
| Biofos A/S | 5 | 0.4% |
| Guldborgsund Forsyning A/S | 5 | 0.4% |
What are pharmaceuticals contracts worth in Denmark?
941 of the 1,166 records publish a contract value. The median is $5.2M and the largest single published value is $352.4M. By size, 34 under $100k, 158 between $100k and $1M, 405 between $1M and $10M, 344 above $10M. The remaining 225 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.
| Contract size | Records | Share of priced |
|---|---|---|
| under $100k | 34 | 3.6% |
| between $100k and $1M | 158 | 17% |
| between $1M and $10M | 405 | 43% |
| above $10M | 344 | 37% |
How long do bidders get to respond to pharmaceuticals tenders in Denmark?
Across the 221 Denmark pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 36 days. A quarter of them allowed 35 days or fewer and a quarter stayed open for more than 50. Short turnarounds are the exception rather than the rule here: only 1 (0.5%) closed within a fortnight of being published.
How often are pharmaceuticals tenders published in Denmark?
Denmark publishes about 25 notices a month in this category, 304 in the last twelve months. That is 821% more than the 33 published in the twelve months before that. Over the last three years there were 403, spread across 72 separate months of activity since 14 June 2016. May is historically the busiest month. The most recent was published 17 November 2026.
How does Denmark compare with other pharmaceuticals markets?
Among the 45 countries where GlobalGov holds a comparable pharmaceuticals market, Denmark ranks 12th by number of records. The largest is Poland (9,417 records against 1,166 here). Within Denmark itself, pharmaceuticals is the 3rd largest of the 54 procurement categories tracked here.
Where do the Denmark pharmaceuticals records on this page come from?
These 1,166 records are collected from 4 official sources: TED (1,160), Doffin (4), Hilma (1), the Sweden TED feed (1). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-11-22.
Open Pharmaceuticals tenders in Denmark
Showing 10 of the 24 notices open in this category today. Openness uses the same definition as the Denmark market page: active, not marked awarded, cancelled, closed or expired, and either closing in the future or published within the last 90 days with no stated closing date.
Denmark – Pharmaceutical products – Amgros 2027 1,856.a.
Denmark – Pharmaceutical products – Amgros 2027 1,176.a.
Denmark – Pharmaceutical products – Amgros 2027 1.175.a
Denmark – Pharmaceutical products – Amgros 2027 1,157.b.
Denmark – Pharmaceutical products – Amgros 2027 1,150.a.
Denmark – Pharmaceutical products – Amgros 2027 1,155.a.
Denmark – Pharmaceutical products – Amgros 2027 1,156.b.
Denmark – Pharmaceutical products – Amgros 2027 1.488.a.
Denmark – Pharmaceutical products – Amgros 2027 1.1780.a.
Other procurement categories in Denmark
Pharmaceuticals procurement in other markets
Never Miss a Denmark Government Contract
Finding Denmark tenders usually means a local portal, a local registration and someone who reads the language. Get an alert you can read when a new pharmaceuticals opportunity is published there.
Start Free Trial